Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug–Drug Interactions of Montelukast

Clinical Pharmacology and Therapeutics

Volumn 101, Issue 3, 2017, Pages 406-415

  Varma, M V ^a   Kimoto, E ^a   Scialis, R ^a   Bi, Y ^a   Lin, J ^a   Eng, H ^a   Kalgutkar, A S ^a   El Kattan, A F ^a   Rodrigues, A D ^a   Tremaine, L M ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450 2C8; CYTOCHROME P450 3A; GEMFIBROZIL; ITRACONAZOLE; MONTELUKAST; ORGANIC ANION TRANSPORTER; PROPRANOLOL; RIFAMPICIN; ROSUVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; ACETIC ACID DERIVATIVE; CYTOCHROME P450 3A INHIBITOR; NUCLEIC ACID SYNTHESIS INHIBITOR; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG PROTEIN BINDING; DRUG UPTAKE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER; LIVER CELL; MACACA FASCICULARIS; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; SIMULATION; SINGLE DRUG DOSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; DOSE RESPONSE; DRUG EFFECTS; HAPLORHINI; METABOLISM;

ACETATES; ANIMALS; CLARITHROMYCIN; CYTOCHROME P-450 CYP2C8; CYTOCHROME P-450 CYP3A INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; GEMFIBROZIL; HAPLORHINI; HEPATOCYTES; LIVER; MODELS, BIOLOGICAL; NUCLEIC ACID SYNTHESIS INHIBITORS; ORGANIC ANION TRANSPORTERS; QUINOLINES; RATS; RIFAMPIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY MEMBER 1B1;

EID: 85002646341     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.520     Document Type: Article

References (50)

1. Reiss, T.F., Chervinsky, P., Dockhorn, R.J., Shingo, S., Seidenberg, B. & Edwards, T.B. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch. Intern. Med. 158, 1213–1220 (1998).
2. Nayak, A. A review of montelukast in the treatment of asthma and allergic rhinitis. Expert Opin. Pharmacother. 5, 679–686 (2004).
3. Balani, S. et al. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Drug Metab. Dispos. 25, 1282–1287 (1997).
4. Cheng, H. et al. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm. Res. 13, 445–448 (1996).
5. Chiba, M., Xu, X., Nishime, J.A., Balani, S.K. & Lin, J.H. Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab. Dispos. 25, 1022–1031 (1997).
6. Karonen, T., Filppula, A., Laitila, J., Niemi, M., Neuvonen, P.J. & Backman, J.T. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clin. Pharmacol. Ther. 88, 223–230 (2010).
7. Ogilvie, B.W. et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab. Dispos. 34, 191–197 (2006).
8. Filppula, A.M., Laitila, J., Neuvonen, P.J. & Backman, J.T. Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. Drug Metab. Dispos. 39, 904–911 (2011).
9. VandenBrink, B.M., Foti, R.S., Rock, D.A., Wienkers, L.C. & Wahlstrom, J.L. Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate. Drug Metab. Dispos. 39, 1546–1554 (2011).
10. Backman, J.T., Filppula, A.M., Niemi, M. & Neuvonen, P.J. Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol. Rev. 68, 168–241 (2016).
11. Varma, M.V., Steyn, S.J., Allerton, C. & El-Kattan, A.F. Predicting clearance mechanism in drug discovery: Extended Clearance Classification System (ECCS). Pharm. Res. 32, 3785–3802 (2015).
12. Shitara, Y., Maeda, K., Ikejiri, K., Yoshida, K., Horie, T. & Sugiyama, Y. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm. Drug Dispos. 34, 45–78 (2013).
13. Li, R., Barton, H.A. & Varma, M.V. Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved. Clin. Pharmacokinet. 53, 659–678 (2014).
14. Maeda, K. et al. Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin. Pharmacol. Ther. 90, 575–581 (2011).
15. Varma, M.V. et al. Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide. AAPS J 16, 736–748 (2014).
16. Varma, M.V., Lai, Y., Kimoto, E., Goosen, T.C., El-Kattan, A.F. & Kumar, V. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. Pharm. Res. 30, 1188–1199 (2013).
17. Varma, M.V., Lai, Y., Feng, B., Litchfield, J., Goosen, T.C. & Bergman, A. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm. Res. 29, 2860–2873 (2012).
18. Kimoto, E., Li, R., Scialis, R.J., Lai, Y. & Varma, M.V. Hepatic disposition of gemfibrozil and its major metabolite gemfibrozil 1-O-beta-glucuronide. Mol. Pharm. 12, 3943–3952 (2015).
19. Hirano, M., Maeda, K., Shitara, Y. & Sugiyama, Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab. Dispos. 34, 1229–1236 (2006).
20. Varma, M.V., Lin, J., Bi, Y.A., Kimoto, E. & Rodrigues, A.D. Quantitative rationalization of gemfibrozil drug interactions: consideration of transporters-enzyme interplay and the role of circulating metabolite gemfibrozil 1-O-beta-glucuronide. Drug Metab. Dispos. 43, 1108–1118 (2015).
21. Shen, H. et al. Cynomolgus monkey as a potential model to assess drug interactions involving hepatic organic anion transporting polypeptides: in vitro, in vivo, and in vitro-to-in vivo extrapolation. J. Pharmacol. Exp. Ther. 344, 673–685 (2013).
22. Takahashi, T. et al. Pitavastatin as an in vivo probe for studying hepatic organic anion transporting polypeptide-mediated drug-drug interactions in cynomolgus monkeys. Drug Metab. Dispos. 41, 1875–1882 (2013).
23. Chu, X. et al. Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans. Drug Metab. Dispos. 43, 851–863 (2015).
24. Brännström, M. et al. Montelukast disposition: no indication of transporter-mediated uptake in OATP2B1 and OATP1B1 expressing HEK293 cells. Pharmaceutics 7, 554–564 (2015).
25. Eley, T. et al. Organic anion transporting polypeptide-mediated transport of, and inhibition by, asunaprevir, an inhibitor of hepatitis C virus NS3 protease. Clin. Pharmacol. Ther. 97, 159–166 (2015).
26. Roth, M., Timmermann, B.N. & Hagenbuch, B. Interactions of green tea catechins with organic anion-transporting polypeptides. Drug Metab. Dispos. 39, 920–926 (2011).
27. Wang, X., Wolkoff, A.W. & Morris, M.E. Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab. Dispos. 33, 1666–1572 (2005).
28. Tamraz, B. et al. OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis. Pharmacogenetic Genomic 23, 355 (2013).
29. Backman, J.T., Kyrklund, C., Neuvonen, M. & Neuvonen, P.J. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. 72, 685–691 (2002).
30. Niemi, M., Backman, J.T., Neuvonen, M. & Neuvonen, P.J. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46, 347–351 (2003).
31. Karonen, T., Neuvonen, P.J. & Backman, J.T. CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. Br. J. Clin. Pharmacol. 73, 257–267 (2012).
32. Jacobson, T.A. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am. J. Cardiol. 94, 1140–1146 (2004).
33. Mougey, E.B., Lang, J.E., Wen, X. & Lima, J.J. Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. J. Clin. Pharmacol. 51, 751–760 (2011).
34. EMA. Guideline on the Investigation of Drug Interactions. Committee for Human Medicinal Products (CHMP). (2012).
35. USFDA. Drug interaction studies — study design, data analysis, implications for dosing, and labeling recommendations. Center for Drug Evaluation and Research (CDER), (2012).
36. Varma, M.V., Pang, K.S., Isoherranen, N. & Zhao, P. Dealing with the complex drug-drug interactions: towards mechanistic models. Biopharm. Drug Dispos. 36, 71–92 (2015).
37. Kalliokoski, A., Neuvonen, M., Neuvonen, P.J. & Niemi, M. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. Br. J. Clin. Pharmacol. 65, 78–86 (2008).
38. Kalgutkar, A.S. et al. Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activated receptor alpha. Xenobiotica 43, 963–972 (2013).
39. Bi, Y.A., Kazolias, D. & Duignan, D.B. Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab. Dispos. 34, 1658–1665 (2006).
40. Jones, H.M. et al. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab. Dispos. 40, 1007–1017 (2012).
41. Nakagomi-Hagihara, R., Nakai, D., Tokui, T., Abe, T. & Ikeda, T. Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1. Xenobiotica 37, 474–486 (2007).
42. Schneck, D.W. et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. 75, 455–463 (2004).
43. Nakagomi-Hagihara, R., Nakai, D. & Tokui, T. Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. Xenobiotica 37, 416–426 (2007).
44. Barton, H.A. et al. Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. Expert Opin. Drug Metab. Toxicol. 9, 459–472 (2013).
45. Varma, M.V. et al. Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin. Drug Metab. Dispos. 41, 966–974 (2013).
46. Varma, M.V., Bi, Y.A., Kimoto, E. & Lin, J. Quantitative prediction of transporter- and enzyme-mediated clinical drug-drug interactions of organic anion-transporting polypeptide 1B1 substrates using a mechanistic net-effect model. J. Pharmacol. Exp. Ther. 351, 214–223 (2014).
47. Niemi, M., Neuvonen, P.J. & Kivisto, K.T. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin. Pharmacol. Ther. 70, 58–65 (2001).
48. Jones, H. et al. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin. Pharmacol. Ther. 97, 247–262 (2015).
49. Obach, R.S., Lombardo, F. & Waters, N.J. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab. Dispos. 36, 1385–1405 (2008).
50. Hegazy, S.K., Mabrouk, M.M., Elsisi, A.E. & Mansour, N.O. Effect of clarithromycin and fluconazole on the pharmacokinetics of montelukast in human volunteers. Eur. J. Clin. Pharmacol. 68, 1275–1280 (2012).